Acorda's Risks With Fampridine Development Look Likely To Pay Off

Acorda took a risk developing a multiple sclerosis drug with a novel indication - improvement in walking ability - that had never before been studied, but it has passed a major hurdle in the form of an advisory committee review, where the clinical community got a chance to weigh in on the effort